A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide — also known as Ozempic — in suppressing ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Whoopi Goldberg has stunned in her latest looks showing off her 100+ pound weight loss after taking popular weight loss drug ...

Novo Nordisk (NVO) said Wednesday that it launched a direct-to-patient online pharmacy through which it will offer its weight loss injection at more than half the list price. The company's NovoCare ...

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before ...

Expanding coverage and access to GLPs can be beneficial for all with the cooperation of multiple parties in health care.

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within 1 year.

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

A product development expert explains how the swift rise of these anti-obesity medications is fueling new food trends.

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared with dipeptidyl peptidase-4 ...